The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
Thrombosis-related edema and lymphedema are two principal types of lower extremity edema results from radiotherapy alone or chemoradiotherapy for patients with cervical cancer. To characterize differences between them, a retrospective study was performed. We collected data including age, race, body weight, FIGO stage, histology type, platelet count, haemoglobin, time of definitely diagnosis, therapeutic regimen, edema type and which leg edema firstly occurred in. Of 40 patients who were eligible for this study, 32 were diagnosed as thrombosis-related edema and 8 diagnosed as lymphedema. The differences in patient age (p = 0.004), propotion of race (p = 0.021), the latent time (p = 0.002) and the mean platelet count (p = 0.019) were statistically significant. Among 32 patients with thrombosis-related edema, 34.4% were in stage II and 53.1% in stage III, 78.1% were squamous cell carcinoma. Among 8 patients with lymphedema, 87.5% were in stage II and 62.5% were squamous cell carcinoma. The differences were not statistically significant for weight (p = 0.94), histology type (p = 0.648), edema site (p = 0.236), haemoglobin (p = 0.088) between the two grouping patients. Although the small patient cohort is a limitation, the results suggest that the patients with thrombosis-related edema may have higher proportion, lower age, shorter latent edema time and more platelet count than those with lymphedema. Also, thrombosis-related edema was likely inclined to Uigur and lymphedema to Han race. We did not find statistical differences in weight, edema site, histology type and haemoglobin between patients with thrombosis-related edema and lymphedema.
Center of Oncology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, China. wp1123456@126.com
Pei-Liang
PL
Wang
Yong-Bo
YB
Cheng
Gulina
G
Kuerban
D000230:Adenocarcinoma / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D001918:Brachytherapy / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D059248:Chemoradiotherapy / Q000009:adverse effects*; D002681:China / Q000453:epidemiology; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004487:Edema / Q000097:blood / Q000208:ethnology / Q000209:etiology*; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007866:Leg; D008209:Lymphedema / Q000097:blood / Q000208:ethnology / Q000209:etiology*; D008875:Middle Aged; D009367:Neoplasm Staging; D010976:Platelet Count; D011882:Radiotherapy, High-Energy / Q000009:adverse effects*; D012189:Retrospective Studies; D019851:Thrombophilia / Q000097:blood / Q000209:etiology; D013927:Thrombosis / Q000150:complications* / Q000208:ethnology / Q000209:etiology; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D014750:Vincristine / Q000008:administration & dosage
D018906:Antineoplastic Agents, Alkylating; D006454:Hemoglobins; D001761:Bleomycin; D014750:Vincristine; D002945:Cisplatin; D005472:Fluorouracil; D007069:Ifosfamide